SCHEMBL4197379

SCHEMBL4197379

CCO/C=C(/C(C)=O)C(=O)OCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.67
NPSR1 Q6W5P4 4/20 0.50
ALDH1A1 P00352 7/20 0.44
CYP2D6 P10635 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 8/20 0.43
KMT2A Q03164 8/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 5/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 9/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1186672 1.00 GLO1 (0.67) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL1186674 1.00 GLO1 (0.67) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL50838 0.89 NPSR1 (0.56) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL24937270 0.88 GLO1 (0.57) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL28786257 0.88 GLO1 (0.57) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL29636860 0.88 GLO1 (0.53) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11651953 0.86 GLO1 (0.50) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11651951 0.86 GLO1 (0.50) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL2364222 0.85 GLO1 (0.50) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL824578 0.84 GLO1 (0.48) GLO1NPSR1ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 EP disclosed
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-06-12 US disclosed
EP-4551555-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 EP disclosed
US-12264159-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2025-04-01 US disclosed
CN-119677716-A Pharmaceutical compositions comprising WRN helicase inhibitors 维维迪恩医疗公司 2025-03-21 CN disclosed
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors VIVIDION THERAPEUTICS, INC. 2025-01-07 US disclosed
CN-118515653-B EZH2 specific inhibitor and preparation method and application thereof 西湖制药(杭州)有限公司 2024-12-10 CN disclosed
CN-115279767-B Tetracyclic compounds as inhibitors of hepatitis b surface antigen 正大天晴药业集团股份有限公司 2024-12-06 CN disclosed
CN-118515653-A EZH2 specific inhibitor and preparation method and application thereof 西湖制药(杭州)有限公司 2024-08-20 CN disclosed
US-20240262828-A1 Functionalized Heterocycles as Antiviral Agents ENANTA PHARM INC (US) 2024-08-08 US disclosed
EP-1682535-A1 HETEROARYL DERIVATIVES AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
US-6995263-B2 Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2006-02-07 US disclosed
WO-2005049606-A1 HETEROARYL DERIVATIVES AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096353-A1 Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed
US-20040248872-A1 Difluoroalkene derivative, pest control agent containing the same, and intermediate therefor IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2004-12-09 US disclosed
EP-1439169-A1 DIFLUOROALKENE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE SAME, AND INTERMEDIATE THEREFOR KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2004-07-21 EP disclosed
US-4837238-A Pharmacologically useful pyrazolopyridines BEECHAM GROUP P.L.C. (GB) 1989-06-06 US disclosed
EP-0193329-A2 Pyrazolopyridines, their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1986-09-03 EP disclosed
US-4167568-A TREATMENT OF RESPIRATORY SYSTEM DISORDERS, ANTIHISTAMINES MAY & BAKER LIMITED (GB) 1979-09-11 US disclosed
US-4104049-A Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262828-A1 Functionalized Heterocycles as Antiviral Agents HCCS, HAVCR2, HDGF GLO1 2628/4885NPSR1 1922/4885ALDH1A1 2352/4885
US-20040248872-A1 Difluoroalkene derivative, pest control agent containing the same, and intermediate therefor DDT, WEE1, NOTUM GLO1 33/4885NPSR1 2069/4885ALDH1A1 875/4885
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors RECQL, BLM, WRN GLO1 1439/4885NPSR1 4482/4885ALDH1A1 2371/4885
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN GLO1 1439/4885NPSR1 4482/4885ALDH1A1 2371/4885
US-20050096353-A1 Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG GLO1 4095/4885NPSR1 510/4885ALDH1A1 788/4885
US-12264159-B2 Functionalized heterocycles as antiviral agents HCCS, HAVCR2, HDGF GLO1 2628/4885NPSR1 1922/4885ALDH1A1 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.